Patents Assigned to Chiesi Farmaceutici S.p.A.
  • Kinase inhibitors
    Patent number: 9758521
    Abstract: Compounds of formulae (I), (II), and (III), defined herein, are p38 MAPK inhibitors and are useful as anti-inflammatory agents in the treatment of, inter alia, diseases of the respiratory tract.
    Type: Grant
    Filed: December 22, 2016
    Date of Patent: September 12, 2017
    Assignee: CHIESI FARMACEUTICI S.p.A.
    Inventors: Carmelida Capaldi, Elisabetta Armani, Andrew Steven Robert Jennings, Christopher Hurley
  • Pyridazinone derivatives as phoshoinositide 3-kinases inhibitors
    Patent number: 9745308
    Abstract: Compounds of formula (I) described herein inhibit phosphoinositide 3-kinases (PI3K) and useful for the treatment of disorders associated with PI3K enzymes.
    Type: Grant
    Filed: August 31, 2015
    Date of Patent: August 29, 2017
    Assignee: CHIESI FARMACEUTICI S.p.A.
    Inventors: Matteo Biagetti, Anna Maria Capelli, Matilde Guala
  • PYRAZOLE DERIVATIVES AS PHOSPHOINOSITIDE 3-KINASES INHIBITORS
    Publication number: 20170226109
    Abstract: Compounds of formula (I) defined herein are phosphoinositide 3-kinases (PI3K) inhibitors and are useful for the treatment of disorders associated with PI3K enzymes.
    Type: Application
    Filed: January 31, 2017
    Publication date: August 10, 2017
    Applicant: CHIESI FARMACEUTICI S.p.A.
    Inventors: Matteo BIAGETTI, Anna Maria CAPELLI, Michele RETINI
  • PREPARATION OF MICRONIZED PARTICLES OF AN ANTIMUSCARINIC COMPOUND BY HYDRODYNAMIC CAVITATION
    Publication number: 20170209414
    Abstract: Crystalline micronized particulate of a glycopyrronium salt may be prepared by hydrodynamic cavitation. The resulting drug particles are physically stable with regard to agglomeration and/or aggregation on storage.
    Type: Application
    Filed: January 19, 2017
    Publication date: July 27, 2017
    Applicant: CHIESI FARMACEUTICI S.P.A.
    Inventors: Stephen P. DAVANZO, Barry E. NALL, Timothy J. ROUSE, Michele MIOZZI
  • Pharmaceutical formulations comprising high purity cangrelor and methods for preparing and using the same
    Patent number: 9700575
    Abstract: The present invention relates to high purity cangrelor, pharmaceutical formulations comprising high purity cangrelor as an active ingredient, methods for preparing such compounds and formulations, and methods for using the pharmaceutical formulations in the inhibition of platelet activation and aggregation.
    Type: Grant
    Filed: June 21, 2016
    Date of Patent: July 11, 2017
    Assignee: Chiesi Farmaceutici, S.P.A.
    Inventors: Panna Dutta, Adel Rafai Far, Min Ding, Rajeshwar Motheram
  • KINASE INHIBITORS
    Publication number: 20170183343
    Abstract: Compounds of formula (I) defined herein are p38 MAPK inhibitors and are useful as anti-inflammatory agents in the treatment of, inter alia, diseases of the respiratory tract.
    Type: Application
    Filed: December 22, 2016
    Publication date: June 29, 2017
    Applicant: CHIESI FARMACEUTICI S.P.A.
    Inventors: Carmelida CAPALDI, Elisabetta ARMANI, Andrew Steven Robert JENNINGS, Christopher HURLEY
  • KINASE INHIBITORS
    Publication number: 20170183344
    Abstract: Compounds of formulae (I), (II), and (III), defined herein, are p38 MAPK inhibitors and are useful as anti-inflammatory agents in the treatment of, inter alia, diseases of the respiratory tract.
    Type: Application
    Filed: December 22, 2016
    Publication date: June 29, 2017
    Applicant: CHIESI FARMACEUTICI S.P.A.
    Inventors: Carmelida CAPALDI, Elisabetta ARMANI, Andrew Steven Robert JENNINGS, Christopher HURLEY
  • KINASE INHIBITORS
    Publication number: 20170183345
    Abstract: Compounds of formula (I) defined herein are p38 MAPK inhibitors and are useful as anti-inflammatory agents in the treatment of, inter alia, diseases of the respiratory tract.
    Type: Application
    Filed: December 22, 2016
    Publication date: June 29, 2017
    Applicant: CHIESI FARMACEUTICI S.P.A.
    Inventors: Carmelida CAPALDI, Elisabetta ARMANI, Andrew Steven Robert JENNINGS, Christopher HURLEY
  • NOVEL COMPOUNDS
    Publication number: 20170166574
    Abstract: Triazolinone compounds of formula (I) defined herein exhibit human neutrophil elastase inhibitory properties and are useful for the therapy of diseases and conditions in which HNE is implicated.
    Type: Application
    Filed: December 12, 2016
    Publication date: June 15, 2017
    Applicant: CHIESI FARMACEUTICI S.P.A.
    Inventors: Elisabetta ARMANI, Carmelida CAPALDI
  • COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY
    Publication number: 20170158694
    Abstract: Compounds of formula (I), defined herein, act both as muscarinic receptor antagonists and beta2 adrenergic receptor agonists and are useful for the prevention and/or treatment of broncho-obstructive or inflammatory diseases.
    Type: Application
    Filed: November 30, 2016
    Publication date: June 8, 2017
    Applicant: CHIESI FARMACEUTICI S.P.A.
    Inventors: Laura CARZANIGA, Fabio RANCATI, Andrea RIZZI, Ian LINNEY
  • 3,5-DICHLORO,4-(3,4-(CYCLO-)ALKOXYPHENYL)--2-CARBONYLOXY)ETHYL)PYRIDINE DERIVATIVES AS PDE-4 INHIBITORS
    Publication number: 20170152256
    Abstract: The invention relates to novel 3,5-dichloro,4-(3,4-(cyclo-) alkoxyphenyl)-2-carbonyloxy)ethyl)pyridine compounds which are inhibitors of the phosphodiesterase 4 (PDE4) enzyme and muscarinic M3 receptor antagonists, methods of preparing such compounds, compositions containing them and therapeutic use thereof.
    Type: Application
    Filed: June 4, 2014
    Publication date: June 1, 2017
    Applicant: Chiesi Farmaceutici S.p.A.
    Inventors: Gabriele AMARI, Elisabetta ARMANI, Mauro RICCABONI, Andrea RIZZI, Charles BAKER-GLENN, Wesley BLACKABY, Herve VAN DE POEL, Ben WHITTAKER
  • Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
    Patent number: 9662323
    Abstract: Compounds of formula I, defined herein, act both as muscarinic receptor antagonists and beta2 adrenergic receptor agonists and are useful for treating diseases of the respiratory tract.
    Type: Grant
    Filed: May 31, 2016
    Date of Patent: May 30, 2017
    Assignee: CHIESI FARMACEUTICI S.p.A.
    Inventors: Laura Carzaniga, Fabio Rancati, Andrea Rizzi, Ian Linney, Wolfgang Schmidt, Michael Barnes, Chris Knight
  • 3,5-DICHLORO,4-(3,4-(CYCLO-)ALKOXYPHENYL)- 2-CARBONYLOXY)ETHYL)PYRIDINE DERIVATIVES AS PDE-4 INHIBITORS
    Publication number: 20170145004
    Abstract: The invention relates to novel 3,5-dichloro,4-(3,4-(cyclo-) alkoxyphenyl)-2-carbonyloxy)ethyl)pyridine compounds which are both inhibitors of the phosphodiesterase 4 (PDE4) enzyme and muscarinic M3 receptor antagonists, methods of preparing such compounds, compositions containing them and therapeutic use thereof.
    Type: Application
    Filed: June 4, 2014
    Publication date: May 25, 2017
    Applicant: CHIESI FARMACEUTICI S.p.A.
    Inventors: Gabriele AMARI, Elisabetta ARMANI, Mauro RICCABONI, Charles BAKER-GLENN
  • PROCESS FOR PREPARING A DRY POWDER FORMULATION COMPRISING AN ANTICHOLINERGIC, A CORTICOSTEROID AND A BETA-ADRENERGIC
    Publication number: 20170136034
    Abstract: Dry powder formulations for inhalation comprising a combination of an anticholinergic, a long-acting beta2-adrenoceptor agonist, and, optionally, an inhaled corticosteroid are useful for the prevention and/or treatment of an inflammatory and/or obstructive airways disease.
    Type: Application
    Filed: November 15, 2016
    Publication date: May 18, 2017
    Applicant: CHIESI FARMACEUTICI S.P.A.
    Inventors: Claudio CAFIERO, Leonardo ORTENZI
  • PROCESS FOR PREPARING A DRY POWDER FORMULATION COMPRISING AN ANTICHOLINERGIC, A CORTICOSTEROID AND A BETA-ADRENERGIC
    Publication number: 20170136035
    Abstract: Dry powder formulations for inhalation containing a combination of an anti-cholinergic, a long-acting beta2-adrenoceptor agonist, and a corticosteroid are useful for the prevention and/or treatment of an inflammatory and/or obstructive airways disease.
    Type: Application
    Filed: November 15, 2016
    Publication date: May 18, 2017
    Applicant: CHIESI FARMACEUTICI S.P.A.
    Inventors: Claudio CAFIERO, Leonardo Ortenzi, Francesca Schiaretti
  • COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY
    Publication number: 20170119753
    Abstract: Compounds of formula I, defined herein, act both as muscarinic receptor antagonists and beta2 adrenergic receptor agonists and are useful for treating broncho-obstructive and inflammatory diseases.
    Type: Application
    Filed: January 12, 2017
    Publication date: May 4, 2017
    Applicant: CHIESI FARMACEUTICI S.p.A.
    Inventors: Fabio RANCATI, Andrea RIZZI, Laura CARZANIGA, Ian LINNEY, Chris KNIGHT, Wolfgang SCHMIDT
  • Aminoester derivatives
    Patent number: 9636336
    Abstract: Compounds of formula (I) defined herein are both phosphodiesterase 4 (PDE4) enzyme inhibitors and muscarinic M3 receptor antagonists and are useful for treating diseases of the respiratory tract.
    Type: Grant
    Filed: May 31, 2016
    Date of Patent: May 2, 2017
    Assignee: CHIESI FARMACEUTICI S.p.A.
    Inventors: Gabriele Amari, Elisabetta Armani, Wesley Blackaby, Herve Van De Poeol, Charles Baker-Glenn, Naimisha Trivedi
  • NOVEL COMPOUNDS
    Publication number: 20170101413
    Abstract: This invention relates to heterocyclic compounds, which are pyrimidinone derivatives having human neutrophil elastase inhibitory properties, and their use in therapy.
    Type: Application
    Filed: June 12, 2014
    Publication date: April 13, 2017
    Applicant: CHIESI FARMACEUTICI S.p.A.
    Inventors: Lilian ALCARAZ, Robert Andrew HEALD, Jonathan Mark SUTTON, Elisabetta ARMANI, Carmelida CAPALDI
  • STABLE PRESSURISED AEROSOL SOLUTION COMPOSITION OF GLYCOPYRRONIUM BROMIDE AND FORMOTEROL COMBINATION
    Publication number: 20170095444
    Abstract: Aerosol solution compositions intended for use with a pressurized metered dose inhaler, comprising glycopyrronium bromide and formoterol, or a salt thereof, optionally in combination with one or more additional active ingredients, and stabilized by a selected amount of a mineral acid, exhibit improved stability when contained in an aerosol can provided with a metering valve having at least a butyl rubber gasket.
    Type: Application
    Filed: December 15, 2016
    Publication date: April 6, 2017
    Applicant: CHIESI FARMACEUTICI S.p.A.
    Inventors: Sauro BONELLI, Diego COPELLI, Massimiliano Dagli ALBERI, Francesca USBERTI, Enrico ZAMBELLI
  • Clevidipine Nanoparticles and Pharmaceutical Compositions Thereof
    Publication number: 20170087093
    Abstract: Provided is a pharmaceutical composition comprising clevidipine in a sterile, ready to use, physically stable, aqueous dispersion of nanoparticles that stabilizes clevidipine against formation of impurities and is suitable for parenteral administration.
    Type: Application
    Filed: May 19, 2015
    Publication date: March 30, 2017
    Applicant: Chiesi Farmaceutici S.p.A.
    Inventors: Rajeshwar Motheram, David C. Hanley, Sr., Akif Emre Tureli, Monika Kanter